Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:20 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder

NCT06673394 · Tianjin Medical University General Hospital · PHASE2 · withdrawn · last registry update 2025-09-10 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“The study plan need to be modified after widely discussion with our consultation board, regarding the conscern about the efficiency may not be able to detect the expected differences. We would like to withdraw this study plan and startup a new one.”	–	Registry record, Tianjin Medical University General Hospital

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against C5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision